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Abstract
Two disease severity scoring systems, the Mainz Severity Score Index (MSSI) and Fabry Disease Severity Scoring System (DS3),
have been validated for quantifying the disease burden of Fabry disease. We aimed to develop a dynamic mathematical model
[the FASTEX (FAbry STabilization indEX)] to assess the clinical stability. Amultidisciplinary panel of experts in Fabry diseasefirst
defined a novel score of severity [raw score (RS)] based on three domains with a small number items in each domain (nervous
system domain: pain, cerebrovascular events; renal domain: proteinuria, glomerular filtration rate; cardiac domain:
echocardiography parameters, electrocardiographparameters andNewYorkHeart Association class) and evaluated the clinical
stability over time. The RSwas tested in 28 patients (15males, 13 females) with the classic formof Fabry disease. Therewas good
statistical correlation between the newly established RS and a weighted score (WS), with DS3 and MSSI (R2 = 0.914, 0.949, 0.910
and 0.938, respectively). In order to refine the RS further, aWS, whichwas expressed as a percentage value, was calculated. This
was based on the relative clinical significance of each item within the domain with the panel agreeing on the attribution of a
different weight of clinical damage to a specific organ system. To test the variation of the clinical burden over time, the RS was
repeated after 1 year. The panel agreed on a cut-off of a 20% change from baseline as the clinical WS to define clinical stability.
The FASTEX model showed good correlation with the clinical assessment and with clinical variation over time in all patients.
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Introduction
Fabry disease is a lysosomal storage disorder caused by defi-
ciency of the enzyme α-galactosidase A (αGal A) that is encoded
by the GLA gene located on the X-chromosome locus Xq21.3-
q22. This deficiency leads to the accumulation of glycosphingoli-
pids, predominately globotriaosylceramide (GL-3) in various cell
types and organs [1, 2], which causes a constellation of complica-
tions including skin lesions, peripheral neuropathy, stroke, ar-
rhythmia, cardiomyopathy and renal failure [2]. Clinical signs
and symptoms may be present in early childhood, and the earli-
est manifestations occurring in the classic form of Fabry disease
include painful peripheral acroparaesthesia and angiokeratoma
[3]. With age, progressive damage to vital organs may lead to
organ failure [2]. End-stage renal disease and life-threatening
cardiovascular or cerebrovascular complications significantly re-
duce life expectancy [4, 5]. A ‘cardiac variant’ has been reported
for patients with predominant or exclusive cardiac involvement
[6, 7]. Female patients with Fabry disease may develop clinical
signs ranging in intensity from being completely asymptomatic
to severe disease similar to men with classic Fabry disease [8,
9]. This clinical variability is partly explained by the random X-
chromosome inactivation (lyonization) [10]. Therefore, as for
men with Fabry disease, assessing signs and symptoms of the
disease in females and monitoring any clinical variation over
time is mandatory [11]. Treatment of Fabry disease is based pri-
marily on enzyme replacement therapy (ERT) with agalsidase
alfa or agalsidase beta. Although ERT may be effective in halting
disease progression when it is introduced at an early stage of the
disease [12], it may not be able to stop disease progression when
first administered in advanced stages. Therefore the ability to as-
sess the degree of disease involvement and/or its stability is quite
useful [13]. Two Fabry disease severity scoring systems, the
Mainz Severity Score Index (MSSI) [14] and the Fabry Disease Se-
verity Scoring System (DS3) [15], and a prognostic score index to
predict natural history and prognosis of a single patient [16] have
been previously validated. These tools provide an index of dis-
ease severity at a single time point, i.e. a snapshot of the clinical
status of the individual patient, and do not allow evaluation of
the clinical course over time. To date, there are no instruments
that can demonstrate clinical stability, which represents an im-
portant goal in the management of patients with Fabry disease.
Clinical stability of treated patients is indicative of the efficacy
of ERT, and untreated patients who become clinically unstable
may need to be initiated on treatment with ERT. However, to
date there are no validated instruments that reliably assess clin-
ical stability, which is a cornerstone of the management of pa-
tients with Fabry disease. Therefore we have developed a
mathematical model [the FAbry STabilization indEX (FASTEX)]
in order to objectively verify whether patients with Fabry disease
remain clinically stable or become unstable over time.
Subject andmethods applied to develop the raw
score, weighted score and FASTEX
Consensus conference for raw score
During the first meeting in February 2014, relevant Fabry disease
domains were identified using the Nominal Group Technique
(NGT) of consensus formation [17]. The consensus defined a
new score, the raw score (RS), based on 5-point Likert items [18]
with three domains: nervous system, renal and cardiac. The do-
mains contain the following items:
• Nervous system: pain, cerebrovascular events
• Renal: proteinuria and/or urinary albumin excretion, esti-
mated glomerular filtration rate (eGFR)
• Cardiac: echocardiography parameters, electrocardiograph
parameters, New York Heart Association (NYHA) class.
A scoring system ranging from 0 (no damage) to 4 (severe dam-
age) was used for each of these seven items (Table 1).
The panel of experts involved on this project evaluated the RS
jointly. Based on literature reviews [2, 14, 15, 19, 20] and personal
routine clinical practice of following patients with Fabry disease,
the panel reached a consensus on the hierarchy and score ap-
plied to each item and domain.
Consensus conference for weighted Score
During the second meeting in June 2014, a weighted score (WS)
related to the clinical domains was discussed. The WS was pro-
posed in order to capture the relative importance of progression
from one RS to a higher score in each domain and it was derived
from the RS according to the previously agreed hierarchy of clin-
ical impact of organ involvement. It was expressed as a percent-
age of the maximum involvement score in each organ system
(Table 2). Percentages of WS, as shown in Table 2, were approved
by the panel members based on their personal clinical experi-
ence and articles/reviews published in the literature [2, 14, 15,
19, 20].
Consensus conference for clinical status
During the lastmeeting, held in October 2014, the panel analysed
and reported the clinical status of the patients in the study using
RSs and WSs. In addition, for each patient included in the study,
the DS3 and MSSI scores were calculated. These four different
scales used to calculate the clinical status of the patients were
needed to verify and calculate the statistical correlation between
RS, WS, DS3 and MSSI (Table 4). The demonstration of good stat-
istical correlation with MSSI and DS3, which are two severity
score systems already validated in the literature, was necessary
to showthatRS, and subsequentlyWS, are two equally valid scor-
ing systems, but utilizing a smaller number of variables that are
also more objective and easier to assess, to evaluate disease se-
verity. Since the FASTEX score is calculated from WS, which is
based on RS, a good statistical correlation between RS, WS,
MSSI and DS3 was required.
Application for RS, WS and Fastex
The aim of our study was to develop a mathematical model able
to objectively verify whether patients with Fabry disease can be
considered clinically stable or unstable during their clinical
course.
A multidisciplinary panel of seven clinicians (cardiologists,
nephrologists, neurologists, a paediatrician), all experts in the
clinical management of Fabry disease, and two methodologist-
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biostatisticians was established in 2014. A series of meetings
were convened in order to study and develop a newmathematic-
al model, the FASTEX.
To generate FASTEX, a new severity score system for Fabry
disease had to be created. In order to be easily applicable in clin-
ical practice, it needed to be a simpler, faster and more practical
method to calculate disease severity than DS3 and MSSI.
Since the disease severity score in itself does not reflect either
a clinical or an objective value of organ damage, we created a se-
cond score, theWS. TheWS is an innovative new scoring system
based on the individual items of the RS and is intended to reflect
the degree of organ damage for each domain.
The concept of clinical stability depends on the variability of
the condition of patients with Fabry disease over time. To reflect
the spectrumof disease variability in patientswith Fabry disease,
we tested both the RS andWS in a population of 28 Fabry disease
patients with different degrees of organ involvement at baseline
(visit 1) and after 1 year (visit 2). The difference in theWSbetween
the two clinical assessments resulted in the FASTEX score.
Patient population
The patient population consisted of 28 Fabry disease patients [15
males (mean age 36 ± 18 years, range 8–65 years) and 13 females
(mean age 47 ± 13 years, range 27–63 years)] with varying degrees
of disease burden and followed at the authors’ centres. All pa-
tients enrolled in this study presented with the classic form of
Fabry disease and a genotype associated with the classic disease
pattern. The baseline (visit 1) analysis of the clinical condition of
the patients is shown in Table 3.
Statistical analysis
To assess long-term stability, the FASTEX takes into account, to-
gether with the RS, the status of the parameters at two different
temporal points. Through the allocation of their respective
weights, these scores are converted into percentages (WS;
Table 2). The scores are reported in a graph where, for each par-
ameter, it is possible to determine the extent of worsening/im-
provement during the time interval between two visits. The
overall stability of the disease is obtained from the sum of wor-
sening or improving scores.
The severity of each domain was calculated using the
root mean square (RMS) of the respective items related to
Table 1. Raw score: nervous, renal and cardiac systems
Nervous system score
Score Pain Score Events
0 None 0 None
1 Mild without treatment 1 Hyperintensity of white matter
2 Moderate without treatment 2 TIA
3 Present and controlled with therapy 3 ischaemic or haemorrhagic
4 Present and not controlled with therapy 4 Recurrent TIA or stroke
Renal system score
Score Albuminuria (ACR)/proteinuria (PCR) Score eGFR
0 ACR <22 mg/g (or <2.5 mg/mmol) 0 <135 mL/min >90 mL/min
1 ACR 22–299 mg/g (or 2.5–29 g/mmol) 1 >135 mL/min (Hyper filtration)
2 PCR >300 ≤ 499 mg/g 2 <90–≥60 mL/min
3 PCR >500 ≤ 799 mg/g 3 ≤59–≥30 mL/min
4 PCR >800 mg/g 4 ≤29 mL/min
Cardiac system score
Score LVH Score ECG/arrhythmia Score NYHA
0 No LVH 0 None 0
1 Diastolic dysfunction 1 Short PQ, ST alteration 1 I
2 Mild LVH (11.5–13.5 mm) 2 LVH on ECG 2 II
3 Moderate LVH (>13.5–15 mm) or Fibrosis MRI 3 AVB, PSVT, AF, NSVT, bradycardia 3 III
4 Severe LVH (>15 mm) 4 PM, ICD 4 IV
AVB, atrio-ventricular block; AF, atrial fibrillation; ACR, urinary albumin:creatinine ratio; eGFR, estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology
Collaboration); ECG, electrocardiogram; ICD, implantable cardiac defibrillator; LVH, left ventricular hypertrophy; NSVT, non-sustained ventricular tachycardia; PCR,
urinary protein:creatinine ratio; PM, pacemaker; PSVT, paroxysmal supraventricular tachycardia; TIA, transitory ischaemic attack.
Table 2.Weighted score expressed as a percentage of organ damage
Raw score (0–4) 0 1 2 3 4
Nervous system
Pain % 0 5 20 40 100
Events % 0 10 30 60 100
Renal
ACR /PCR % 0 35 55 65 100
eGFR % 0 10 50 80 100
Cardiac
LVH % 0 10 40 60 100
ECG/arrhythmia % 0 25 45 70 100
NYHA % 0 40 60 80 100
ACR, urinary albumin:creatinine ratio; PCR, urinary protein:creatinine ratio; eGFR,
estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology
Collaboration); ECG, electrocardiogram; LVH, left ventricular hypertrophy.
Table 3. Clinical involvement at baseline (visit 1)
Involvement Patient# Nervous system Renal Cardiac
Single organ 6 3 – 3
Two organsa 7 3 7 4
Multiple organs 10 10 10 10
No organ damage 5 – – –
On ERT at baseline 24
ERT, enzyme replacement therapy.
aThree cases had nervous system and renal involvement; four cases had cardiac
and renal involvement.
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that domain expressed as a percentage. The RMS method
enables distinguishing the result of equal sums obtained
from components with different values. By using RMS, it is
possible to calculate any combination of scores for any poten-
tial hypothetical patient and for all domains (Supplementary
data).
The overall severity of the disease, reported as a percentage,
was calculated as the sum of each severity domain corrected by
their interaction, as shown in the following algorithm:
100  ðAþ ð1AÞ  Bþ ð1 ðAþ ð1 AÞ  BÞÞ  CÞ; ð1Þ
which simplifies to:
100  ðAþ Bþ Cþ A  B  CA  B A  C B  CÞ ð2Þ;
where A = RMS of the nervous system domain, B = RMS of the
renal domain and C = RMS of the cardiac domain.
Using this algorithm, we ascertain that if there is only one
compromised domain, the patient’s total disease severity equals
the value of this domain. Finally, if the severity of each domain is
lower than the maximum severity (100%), the formula provides
an higher result proportional to the severity of the most severely
affected domain (Figure 1).
All combinations of scores for each domain system
(nervous, renal and cardiac) calculated by applying the algo-
rithm specified above are provided in the Supplementary
data. These values represent all possible combinations of
percentages for organ damage subdivided for each domain
(Figures 2 and 3).
Results
Coefficient of correlation between RS, WS, DS3
and MSSI
Coefficients of correlation (r2) between the different scoring sys-
tems were good (Table 4), even with the relatively small sample
size. This finding is in line with the fact that the new scores
were developed based on previously published scores [14, 15].
However, our new model is faster and easier to use. To test the
adherence with other published disease severity indices, a spe-
cific coefficient of correlation was calculated between RS, WS,
DS3 and MSSI, as shown in Table 4.
Clinical stability
Theworking group reached a consensus on a score (FASTEX) to be
able to determine when a patient can be considered stable or un-
stable. Following thismethod and applying this concept to the al-
gorithm, any worsening with a global score ≥20% suggests that
the patient is clinically unstable, regardless of the result of the
sum of the improvement scores. It is important to underline
that the interpretation becomes more problematic when, in the
same patient, there is evidence of improvement in some para-
meters but worsening in other parameters. Since quantifying
the balance between improvement and worsening is very diffi-
cult from a statistical point of view, the working panel reviewed
the clinical variation between visits and agreed that a variation
in the clinical status of the FASTEX score≥20% is anunstable clin-
ical condition while a score of <20% corresponds to a stable clin-
ical condition.
Illustrative cases of clinically stable and unstable patients
are provided below
Example 1 – Patient not stable (atrial fibrillation present at the se-
cond visit while no cardiac abnormality was present at baseline)
(Table 5).
WS =Weighed Score/(RS) = (Raw Score)
• Change in the severity score of the cardiac domain: ECG/ar-
rhythmia from 0 to 45%;
• FASTEX = 45% (>20%)
Example 2 – Patient stable despite mild clinical worsening: the
patient refers the onset of pain at the extremities and there is
mild hyperfiltration at the second visit as compared to baseline,
but the FASTEX is <20% (Table 6).
WS (RS) =Weighed Score (Raw Score)
• Change in nervous system domain: pain from 0 to 5%;
• Change in renal domain: eGFR from 0 to 10%
• FASTEX = 15% (<20%)
Example 3 – Patient not stable despite some clinical improve-
ment: after visit 1, when the patient started ERT; at the second
visit, pain becomesmild but renal function shows hyperfiltration
and a short PR interval is present on thr ECG (Table 7).
WS (RS) =Weighed Score (Raw Score)
• Change in nervous system domain: pain from 20 to 5% (−15%)
• Change in renal domain: eGFR from 0 to 10% (+10%)
• Change in cardiac domain: EKG/arrhythmia from 0 to 25%
(+25%)
• FASTEX = +35% (>20%)
Discussion
To date, two severity scoring systems (MSSI and DS3) to quantify
the disease burden in Fabry disease have been validated [14, 15].
Both of these require evaluation of several domains with a large
number of items (5 domains and 12 items for DS3 and 4 domains
and 24 items for MSSI) resulting in a time-consuming and poten-
tially difficult calculation and application of the indices. In add-
ition, some items of these indices are based largely on patients’
self-reported evaluation of symptoms. Furthermore, these scor-
ing systems only permit static snapshots of the clinical status
of the patient at the time of the visitwithout providing an estima-
tion of the clinical variation as compared with previous visits.
Although the concept of disease stabilization is an important
therapeutic goal in the management of Fabry disease, there are
currently no easy and reliable tools available to define and meas-
ure stability without performing biopsies to quantify GL-3 accu-
mulation in capillary endothelial cells, renal cells (podocytes,
tubular cells, glomerular endothelial, mesangial and interstitial
cells), cardiac cells (cardiomyocytes and fibroblasts) and the cells
of the peripheral, autonomic and central nervous systems [2].
Fabry disease is a progressive disease and periodic evaluation
of the clinical status ismandatory. Aworldwide consensus on the
exact timing for starting ERT andwhether it should be stopped in
the later stages of the disease has not yet been established. Re-
cent reports suggest starting ERT at the time of the diagnosis in
males and in symptomatic females, while in asymptomatic fe-
males the current opinion is to monitor the patient and start
ERT at the onset of signs or symptoms of the disease [19]. Periodic
evaluation allows for early detection of disease progression in
asymptomatic patients not yet receiving ERT and to assess dis-
ease stability or progression, particularly in patients with
742 | R. Mignani et al.
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advanced organ involvement at baseline. Both ERT and adjunct-
ive therapies are directed at relieving symptoms, protecting or-
gans and arresting disease progression.
The aim of our study was to develop an index of stability/
change of state for monitoring of patients with Fabry disease.
First, we generated a new severity score, the RS, based on only
Fig. 1. (A) Percentage severity of single domains and total severity score. (B) Total percentages of severity for single domains and total severity score atfirst and second visit
calculated by applying the algorithm.
Fastex: Fabry Stabilization Index | 743
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three domains and seven items. As compared with the DS3 and
MSSI indexes, our scoring method is simpler, more practical
and faster to calculate and therefore easier to apply in clinical
practice.
To take into account the relative importance of each of the
items, we then introduced theWS. Both the RS andWSwere stat-
istically correlatedwith theMSSI andDS3, showing that the same
accuracy can be obtained by including a smaller number of items
Fig. 2. (A) Percentage severity of single domains and total severity score. (B) Total percentages of severity for single domains and total severity score atfirst and second visit
calculated by applying the algorithm.
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in the calculation of the score. The proposed scores are also likely
to be more objective because a number of items in the MSSI and
DS3, e.g. pain intensity, are dependent on a subjective evaluation
by the patient. Moreover, no differences in the clinical presenta-
tion between the new index (FASTEX) and the twovalidatedmod-
els (DS3 and MSSI) have been observed. The main innovation,
Fig. 3. (A) Percentage severity of single domains and total severity score. (B) Total percentages of severity for single domains and total severity score atfirst and second visit
calculated by applying the algorithm.
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when compared with the DS3 and MSSI, is the introduction of an
overall score taking into account the scores of single organs.
Since the concept of stability depends on the variation of the clin-
ical condition of patients with Fabry disease over time, we ap-
plied and calculated both RS and WS in a population of 28
Fabry disease patients with different degrees of organ involve-
ment at baseline (visit 1) and after 1 year (visit 2). The difference
in the WS between the two clinical assessments resulted in the
FASTEX score. After evaluation of the clinical variation between
visits 1 and 2 of all patients in the study, the working panel re-
viewed the results and agreed to consider a FASTEX score ≥20%
as indicative of clinically significant deterioration of the patient’s
disease, while a score of <20% corresponds to stability or im-
provement of the clinical condition. A FASTEX score of 20% is
therefore to be considered as the threshold limit of stability. A de-
tailed analysis of the follow-up of each patient between visit 1
and 2 confirms that the FASTEX score in each patient correlates
with the follow-up of all the patients enrolled in the study. In
other words, patients with a FASTEX score of <20% do not have
any clinical variation, or at most a small clinical variation at the
second visit as compared with the baseline. Patients with a FAS-
TEX score ≥20% have a significant clinical deterioration during
the follow-up period. Even though the onset of only one new
sign or symptom in a stable patient is indicative of a clinical vari-
ation per se, the FASTEX model allows quantification of the vari-
ation in the same patient over time. In untreated female patients,
the onset of any sign or symptom of the disease with a FASTEX
score >20% may reflect disease progression and warrants thera-
peutic intervention, i.e. starting ERT. In all other patients already
treated with ERT, worsening of the FASTEX score could lead to a
re-evaluation of the therapy with a potential adjustment of the
dose of ERT and/or to the modification of supportive therapy.
A limitation of this new FASTEX model concerns the specific
population of Fabry patients included in the study to test the
model. These patients were routinely monitored at the panel
members’ medical institutes. FASTEX needs to be further vali-
dated in patient populations from other centres. More compre-
hensive data from a larger population may allow further
guidance on how changes over time should be interpreted, par-
ticularly in combination with emerging biomarkers, e.g. globo-
triaosylsphingosine (lyso-GL-3), which is being studied for its
utility in the diagnosis and follow-up of Fabry disease. Explan-
ation of how the algorithm was built to calculate the overall se-
verity of patients is provided in Supplementary data. To avoid
the need to use complex spreadsheet programs, the authors are
currently preparing a free app in order to facilitate wider use of
the FASTEX. This app is intended to be very user friendly: the op-
erator will need to provide the RS index based on the clinical and
laboratory exams and the app will automatically calculate WS
and subsequently the FASTEX index after the second visit.
Conclusions
In summary, a new consensus-based and simpler disease sever-
ity score is proposed thatmay allow quick and easy estimation of
disease stability or progression. The FASTEX should be applied by
clinicians from different international groups to confirm the ac-
curacy and value of this new clinical tool that may contribute
to better clinical assessment and management of patients with
Fabry disease. Since this score needs to be validated in awider co-
hort, full validationwill requiremore extensive retrospective and
prospective studies in different populations of patients with
Fabry disease.
Supplementary data
Supplementary data are available online at http://ndt.oxfordjour-
nals.org.
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